Inhibition of FOS-Like Antigen 1 Reduces Chemoresistance to Temozolomide Through Stemness Reprogramming via IL-6/STAT3^Tyr705 Pathway

Abstract

Glioblastoma (GBM) is the most lethal brain tumor, characterized by strong resistance to conventional therapies. Despite recent therapeutic advancements, overcoming chemoresistance remains a major challenge. Here, we identified FOS-like antigen 1 (FOSL1) as a novel therapeutic target in GBM, particularly in patients with resistance to conventional drugs, including temozolomide (TMZ). FOSL1 gene was identified from the DepMap database as a potential mediator of TMZ resistance in GBM and found to be associated with chemoresistance molecular signatures and poor clinical outcomes. Functional analyses in GBM cells revealed that FOSL1 suppression enhanced apoptosis, induced G0/G1 cell cycle arrest, and reduced both cell migration and stemness marker expression. Transcriptomic profiling, including single-cell RNA-seq and bulk RNA-seq, highlighted the pivotal role of the interleukin-6 (IL-6)/STAT3 signaling pathway in FOSL1-mediated stemness. Mechanistically, in vitro experiments demonstrated that FOSL1 induces GBM stemness through IL-6-pSTAT3^Tyr705 signaling axis. Furthermore, vemurafenib, which targets FOSL1, was identified as a potential therapeutic agent against TMZ-resistant GBM in a mouse model. These findings suggest that FOSL1 promotes TMZ chemoresistance by regulating IL-6-pSTAT3^Tyr705-mediated stemness in GBM cells, making it a promising therapeutic target to overcome chemoresistance in GBM.

Keywords

glioblastoma stemness / glioblastoma / FOSL1 / IL-6 signaling pathway / TMZ chemoresistance

References

[1] J. Lee, S. Narang, J. Martinez, G. Rao, and A. Rao, “Association of Graph-Based Spatial Features With Overall Survival Status of Glioblastoma Patients,” Scientific Reports 13, no. 1 (2023): 17046.

[2] R. Stupp, W. P. Mason, B. MJvd, et al., “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine 352, no. 10 (2005): 987–996.

[3] R. Stupp, M. E. Hegi, W. P. Mason, et al., “Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial,” Lancet Oncology 10, no. 5 (2009): 459–466.

[4] J. R. Perry, P. Rizek, R. Cashman, M. Morrison, and T. Morrison, “Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule,” Cancer 113, no. 8 (2008): 2152–2157.

[5] N. Singh, A. Miner, L. Hennis, and S. Mittal, “Mechanisms of Temozolomide Resistance in Glioblastoma—A Comprehensive Review,” Cancer Drug Resistance 4, no. 1 (2021): 17–43.

[6] S. Y. Lee, “Temozolomide Resistance in Glioblastoma Multiforme,” Genes & Diseases 3, no. 3 (2016): 198–210.

[7] Z. Jihong, F. G. S. Malcolm, and D. B. Tracey, “Temozolomide: Mechanisms of Action, Repair and Resistance,” Current Molecular Pharmacology 5, no. 1 (2012): 102–114.

[8] M. E. Hegi, A.-C. Diserens, T. Gorlia, et al., “MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma,” New England Journal of Medicine 352, no. 10 (2005): 997–1003.

[9] E. M. Goellner, B. Grimme, A. R. Brown, et al., “Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair,” Cancer Research 71, no. 6 (2011): 2308–2317.

[10] B. G. Harder, S. Peng, C. P. Sereduk, et al., “Inhibition of Phosphatidylinositol 3-Kinase by PX-866 Suppresses Temozolomide-Induced Autophagy and Promotes Apoptosis in Glioblastoma Cells,” Molecular Medicine 25, no. 1 (2019): 49.

[11] F. Lan, Q. Pan, H. Yu, and X. Yue, “Sulforaphane Enhances Temozolomide-Induced Apoptosis Because of Down-regulation of miR-21 via Wnt/β-catenin Signaling in Glioblastoma,” Journal of Neurochemistry 134, no. 5 (2015): 811–818.

[12] P. Cui, F. Wei, J. Hou, Y. Su, J. Wang, and S. Wang, “STAT3 Inhibition Induced Temozolomide-Resistant Glioblastoma Apoptosis via Triggering Mitochondrial STAT3 Translocation and Respiratory Chain Dysfunction,” Cellular Signalling 71 (2020): 109598.

[13] E. Shaulian and M. Karin, “AP-1 as a Regulator of Cell Life and Death,” Nature Cell Biology 4, no. 5 (2002): E131–E136.

[14] V. V. Sobolev, A. Z. Khashukoeva, O. E. Evina, et al., “Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis,” International Journal of Molecular Sciences 23, no. 3 (2022): 1521.

[15] K. Maurus, A. Hufnagel, F. Geiger, et al., “The AP-1 Transcription Factor FOSL1 Causes Melanocyte Reprogramming and Transformation,” Oncogene 36, no. 36 (2017): 5110–5121.

[16] A. Khedri, S. Guo, V. Ramar, B. Hudson, and M. Liu, “FOSL1's Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review,” International Journal of Molecular Sciences 25, no. 10 (2024): 5362.

[17] V. Ramar, S. Guo, B. Hudson, et al., “Interaction of NF-κB and FOSL1 Drives Glioma Stemness,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 255.

[18] S. Lin and B. Zhu, “Exosome-Transmitted FOSL1 From Cancer-Associated Fibroblasts Drives Colorectal Cancer Stemness and Chemo-Resistance Through Transcriptionally Activating ITGB4,” Molecular and Cellular Biochemistry 479, no. 3 (2024): 665–677.

[19] L. Li, N. Wang, Y. Xiong, G. Guo, M. Zhu, and Y. Gu, “Transcription Factor FOSL1 Enhances Drug Resistance of Breast Cancer Through DUSP7-Mediated Dephosphorylation of PEA15,” Molecular Cancer Research 20, no. 4 (2022): 515–526.

[20] M. R. Young and N. H. Colburn, “Fra-1 a Target for Cancer Prevention or Intervention,” Gene 379 (2006): 1–11.

[21] K. L. Mooney, W. Choy, S. Sidhu, et al., “The Role of CD44 in Glioblastoma Multiforme,” Journal of Clinical Neuroscience 34 (2016): 1–5.

[22] G. Liu, X. Yuan, Z. Zeng, et al., “Analysis of Gene Expression and Chemoresistance of CD133+ Cancer Stem Cells in Glioblastoma,” Molecular Cancer 5, no. 1 (2006): 67.

[23] H. Lopez-Bertoni, A. Johnson, and Y. Rui, “Sox2 Induces Glioblastoma Cell Stemness and Tumor Propagation by Repressing TET2 and Deregulating 5hmC and 5mC DNA Modifications,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 37.

[24] A. K. Rooj, A. Bronisz, and J. Godlewski, “The Role of Octamer Binding Transcription Factors in Glioblastoma Multiforme,” Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mechanisms 1859, no. 6 (2016): 805–811.

[25] J. Smith, M. Field, and K. Sugaya, “Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma,” Genes 14, no. 6 (2023): 1276.

[26] A. L. V. Alves, I. N. F. Gomes, A. C. Carloni, et al., “Role of Glioblastoma Stem Cells in Cancer Therapeutic Resistance: A Perspective on Antineoplastic Agents From Natural Sources and Chemical Derivatives,” Stem Cell Research & Therapy 12, no. 1 (2021): 206.

[27] L. Casalino, F. Talotta, I. Matino, and P. Verde, “FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer,” International Journal of Molecular Sciences 24, no. 9 (2023): 8307.

[28] N. N. V. Radharani, A. S. Yadav, R. Nimma, et al., “Tumor-Associated Macrophage Derived IL-6 Enriches Cancer Stem Cell Population and Promotes Breast Tumor Progression via Stat-3 Pathway,” Cancer Cell International 22, no. 1 (2022): 122.

[29] H. K. Matthews, C. Bertoli, and R. A. M. de Bruin, “Cell Cycle Control in Cancer,” Nature Reviews Molecular Cell Biology 23, no. 1 (2022): 74–88.

[30] Z. Chen, S. Wang, H.-L. Li, et al., “FOSL1 Promotes Proneural-to-Mesenchymal Transition of Glioblastoma Stem Cells via UBC9/CYLD/NF-κB Axis,” Molecular Therapy 30, no. 7 (2022): 2568–2583.

[31] V. Pecce, A. Verrienti, G. Fiscon, et al., “The Role of FOSL1 in Stem-Like Cell Reprogramming Processes,” Scientific Reports 11, no. 1 (2021): 14677.

[32] Y. Liang, D. Voshart, J. Paridaen, et al., “CD146 Increases Stemness and Aggressiveness in Glioblastoma and Activates YAP Signaling,” Cellular and Molecular Life Sciences 79, no. 8 (2022): 398.

[33] R. Yukimoto, N. Nishida, T. Hata, et al., “Specific Activation of Glycolytic Enzyme Enolase 2 in BRAF V600E-Mutated Colorectal Cancer,” Cancer Science 112, no. 7 (2021): 2884–2894.

[34] M. Rao, B. Shi, Y. Yuan, et al., “The Positive Correlation Between Drug Addiction and Drug Dosage in Vemurafenib-Resistant Melanoma Cells Is Underpinned by Activation of ERK1/2-FRA-1 Pathway,” Anti-Cancer Drugs 31, no. 10 (2020): 1026–1037.

[35] H. M. Neuendorf, J. L. Simmons, and G. M. Boyle, “Therapeutic Targeting of Anoikis Resistance in Cutaneous Melanoma Metastasis,” Frontiers in Cell and Developmental Biology 11 (2023): 1183328.

[36] P. Bai, T. Fan, X. Wang, L. Zhao, R. Zhong, and G. Sun, “Modulating MGMT Expression Through Interfering With Cell Signaling Pathways,” Biochemical Pharmacology 215 (2023): 115726.

[37] W. Huang, Z. Zhong, C. Luo, et al., “The miR-26a/AP-2α/Nanog Signaling Axis Mediates Stem Cell Self-Renewal and Temozolomide Resistance in Glioma,” Theranostics 9, no. 19 (2019): 5497–5516.

[38] D. Xue, X. Zhou, and J. Qiu, “Emerging Role of NRF2 in ROS-Mediated Tumor Chemoresistance,” Biomedicine & Pharmacotherapy 131 (2020): 110676.

[39] Y. Liang, D. Han, S. Zhang, and L. Sun, “FOSL1 Regulates Hyperproliferation and NLRP3-mediated Inflammation of Psoriatic Keratinocytes Through the NF-kB Signaling via Transcriptionally Activating TRAF3,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research 1871, no. 4 (2024): 119689.

[40] A. Khedri, S. Guo, V. Ramar, B. Hudson, and M. Liu, “FOSL1's Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review,” International Journal of Molecular Sciences 25, no. 10 (2024): 5362.

[41] C. Q. Wang, H. T. Sun, X. M. Gao, et al., “Interleukin-6 Enhances Cancer Stemness and Promotes Metastasis of Hepatocellular Carcinoma via Up-regulating Osteopontin Expression,” American Journal of Cancer Research 6, no. 9 (2016): 1873–1889.

[42] A. Hossain, J. Gumin, F. Gao, et al., “Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway,” Stem Cell 33, no. 8 (2015): 2400–2415.

[43] C.-Y. Peng, C.-C. Yu, C.-C. Huang, et al., “Magnolol Inhibits Cancer Stemness and IL-6/Stat3 Signaling in Oral Carcinomas,” Journal of the Formosan Medical Association 121, no. 1 (2022): 51–57.

[44] R. Liu, T. Zhang, G. Zhu, and M. Xing, “Regulation of Mutant TERT by BRAF V600E/MAP Kinase Pathway Through FOS/GABP in Human Cancer,” Nature Communications 9, no. 1 (2018): 579.

[45] K.-H. Kim, S. Migliozzi, H. Koo, et al., “Integrated Proteogenomic Characterization of Glioblastoma Evolution,” Cancer Cell 42, no. 3 (2024): 358–377.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.